RVMD financial statements
The full income statement, balance sheet, and cash-flow statement for Revolution Medicines Inc. (RVMD), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.
Shares outstanding (point-in-time)
SEC-filed end-of-period counts (cover pages and balance sheets, split-adjusted) — the series realized buyback yield is computed from. The weighted-average share lines in the statements below lag these by design: an average over the year sits near the midpoint of an ongoing buyback.
| Line item | Trend | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Income Statement | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| Revenue | 0.00 | 0.00 YoY-100.0% | 11.6M YoY-67.3% | 35.4M YoY+20.4% | 29.4M YoY-31.6% | |
1.18B YoY+71.5% | 690M YoY+38.2% | 499M YoY+69.8% | 294M YoY+35.1% | 217M YoY+41.5% | ||
| Operating income | -1.18B YoY-71.5% | -690M YoY-41.5% | -487M YoY-88.6% | -258M YoY-37.4% | -188M YoY-69.8% | |
| Interest expense | 24.2M | 0.00 | 0.00 | 0.00 YoY-100.0% | 12.0K YoY-83.1% | |
| Interest & investment income | 90.7M YoY+4.4% | 86.9M YoY+83.0% | 47.5M YoY+418.7% | 9.15M YoY+885.4% | 929K YoY-58.5% | |
| Other non-operating income | 51.1M YoY-42.4% | 88.7M YoY+87.5% | 47.3M YoY+416.6% | 9.15M YoY+898.3% | 917K YoY-57.7% | |
| Pre-tax income | -1.13B YoY-88.3% | -601M YoY-36.6% | -440M YoY-76.6% | -249M YoY-33.2% | -187M YoY-72.4% | |
| Income tax | 0.00 YoY+100.0% | -753K YoY+78.6% | -3.52M YoY-739.0% | -420K | 0.00 YoY+100.0% | |
-1.13B YoY-88.5% | -600M YoY-37.5% | -436M YoY-75.5% | -249M YoY-32.9% | -187M YoY-73.0% | ||
-$5.95 YoY-66.2% | -$3.58 YoY+7.3% | -$3.86 YoY-25.3% | -$3.08 YoY-19.8% | -$2.57 YoY-27.9% | ||
| Balance Sheet | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
2.08B YoY-10.9% | 2.33B YoY+23.9% | 1.88B YoY+184.7% | 660M YoY+11.9% | 590M YoY+29.9% | ||
2.35B YoY-8.0% | 2.56B YoY+24.1% | 2.06B YoY+153.9% | 812M YoY+10.0% | 738M YoY+30.1% | ||
290M YoY+77.2% | 164M YoY+13.9% | 144M YoY+132.1% | 62.0M YoY+2.7% | 60.4M YoY+27.9% | ||
723M YoY+146.7% | 293M YoY+24.5% | 236M YoY+85.8% | 127M YoY-6.4% | 135M YoY+46.0% | ||
1.63B YoY-28.0% | 2.27B YoY+24.0% | 1.83B YoY+166.5% | 685M YoY+13.7% | 603M YoY+26.9% | ||
| Cash Flow | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
-898M YoY-61.0% | -557M YoY-59.0% | -351M YoY-56.2% | -224M YoY-52.5% | -147M YoY-47.1% | ||
118M YoY+121.3% | -554M YoY-61.8% | -343M YoY-1320.6% | -24.1M YoY+83.0% | -142M YoY+39.3% | ||
622M YoY-35.2% | 959M YoY-21.9% | 1.23B YoY+307.8% | 301M YoY+2.5% | 294M YoY-30.4% | ||
| Net change in cash | -158M YoY-3.8% | -152M YoY-128.4% | 536M YoY+913.0% | 52.9M YoY+983.9% | 4.88M YoY-94.5% | |
| Valuation Ratios | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| Market cap | 15.8B YoY+94.1% | 8.13B YoY+158.8% | 3.14B YoY+48.6% | 2.11B YoY+13.3% | 1.87B YoY-35.7% | |
| P/S | — | — | 120.1× YoY+67.5% | 71.7× YoY+12.8% | 63.5× YoY-6.0% | |
| P/B | 9.7× YoY+169.5% | 3.6× YoY-4.3% | 3.8× YoY+20.9% | 3.1× YoY+0.2% | 3.1× YoY-49.4% | |
| Source filing | 10-K | 10-K | 10-K | 10-K | 10-K |
About this data
Source: RVMD's SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn't file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all RVMD filings on SEC EDGAR → Not investment advice.
